Rectal cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson, Yi Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman, Charles Fuchs, Jean L Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata RaoDavid P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, Christopher Willett

Research output: Contribution to journalReview article

184 Citations (Scopus)

Abstract

The NCCN Rectal Cancer Guidelines panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important with a goal of evaluating at least 12 nodes when possible. Patients with very early stage tumors lesions that are node-negative by endorectal ultrasound or endorectal or pelvic MRI and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for the majority of patients with suspected or proven T3/T4 disease and/or regional node involvement and adjuvant chemotherapy is recommended. Patients with recurrent localized disease should be considered for resection with or without radiotherapy. A patient with metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered as initial therapy in patients with synchronous or metachronous resectable metastatic disease (i.e., neoadjuvant therapy) or when a response to chemotherapy may convert a patient from an unresectable to resectable state (i.e., conversion therapy). Other options for patients with resectable synchronous metastases are initial treatment with chemoRT or chemotherapy with or without a bevacizumab or cetuximab (KRAS wild type tumor only) followed by consolidating chemoRT. Resection should be followed by adjuvant therapy based on prior therapy received. The recommended post-treatment surveillance program for rectal cancer patients includes serial CEA determinations, as well as periodic chest, abdominal and pelvic CT scans, and periodic evaluations by colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at the start of therapy include pre-planned strategies for altering therapy for patients in both the presence and absence of disease progression, including plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy options for advanced or metastatic disease depend on whether or not the patient is appropriate for intensive therapy. The more intensive initial therapy options include FOLFOX, FOLFIRI, CapeOX, and FOLFOXIRI (category 2B). Addition of a biologic agent (e.g., bevacizumab or cetuximab) is either recommended, or listed as an option, in combination with some of these regimens, depending on available data. Chemotherapy options for patients with progressive disease are dependent on the choice of initial therapy. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

Original languageEnglish (US)
Pages (from-to)838-881
Number of pages44
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number8
DOIs
StatePublished - Sep 2009

Fingerprint

Rectal Neoplasms
Therapeutics
Drug Therapy
Proctoscopy
Radiation Oncology
Neoadjuvant Therapy
Continuity of Patient Care
Medical Oncology
Biological Factors
Gastroenterology
Colonoscopy
Adjuvant Chemotherapy
Radiology
Lung Diseases
Disease Progression
Liver Diseases
Neoplasms
Radiotherapy
Thorax

Keywords

  • Adjuvant chemotherapy
  • Adjuvant radiotherapy
  • Colorectal surgery
  • Fluorouracil
  • Irinotecan
  • NCCN clinical practice guidelines
  • Neoplasm recurrence
  • Neoplasm staging
  • Oxaliplatin
  • Rectal neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y. J., Choti, M. A., Cooper, H. S., ... Willett, C. (2009). Rectal cancer. JNCCN Journal of the National Comprehensive Cancer Network, 7(8), 838-881. https://doi.org/10.6004/jnccn.2009.0057

Rectal cancer. / Engstrom, Paul F.; Arnoletti, Juan Pablo; Benson, Al B.; Chen, Yi Jen; Choti, Michael A.; Cooper, Harry S.; Covey, Anne; Dilawari, Raza A.; Early, Dayna S.; Enzinger, Peter C.; Fakih, Marwan G.; Fleshman, James; Fuchs, Charles; Grem, Jean L; Kiel, Krystyna; Knol, James A.; Leong, Lucille A.; Lin, Edward; Mulcahy, Mary F.; Rao, Sujata; Ryan, David P.; Saltz, Leonard; Shibata, David; Skibber, John M.; Sofocleous, Constantinos; Thomas, James; Venook, Alan P.; Willett, Christopher.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. 8, 09.2009, p. 838-881.

Research output: Contribution to journalReview article

Engstrom, PF, Arnoletti, JP, Benson, AB, Chen, YJ, Choti, MA, Cooper, HS, Covey, A, Dilawari, RA, Early, DS, Enzinger, PC, Fakih, MG, Fleshman, J, Fuchs, C, Grem, JL, Kiel, K, Knol, JA, Leong, LA, Lin, E, Mulcahy, MF, Rao, S, Ryan, DP, Saltz, L, Shibata, D, Skibber, JM, Sofocleous, C, Thomas, J, Venook, AP & Willett, C 2009, 'Rectal cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 8, pp. 838-881. https://doi.org/10.6004/jnccn.2009.0057
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS et al. Rectal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):838-881. https://doi.org/10.6004/jnccn.2009.0057
Engstrom, Paul F. ; Arnoletti, Juan Pablo ; Benson, Al B. ; Chen, Yi Jen ; Choti, Michael A. ; Cooper, Harry S. ; Covey, Anne ; Dilawari, Raza A. ; Early, Dayna S. ; Enzinger, Peter C. ; Fakih, Marwan G. ; Fleshman, James ; Fuchs, Charles ; Grem, Jean L ; Kiel, Krystyna ; Knol, James A. ; Leong, Lucille A. ; Lin, Edward ; Mulcahy, Mary F. ; Rao, Sujata ; Ryan, David P. ; Saltz, Leonard ; Shibata, David ; Skibber, John M. ; Sofocleous, Constantinos ; Thomas, James ; Venook, Alan P. ; Willett, Christopher. / Rectal cancer. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. 8. pp. 838-881.
@article{efd0435161ca4c6ba209f500fdc1d713,
title = "Rectal cancer",
abstract = "The NCCN Rectal Cancer Guidelines panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important with a goal of evaluating at least 12 nodes when possible. Patients with very early stage tumors lesions that are node-negative by endorectal ultrasound or endorectal or pelvic MRI and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for the majority of patients with suspected or proven T3/T4 disease and/or regional node involvement and adjuvant chemotherapy is recommended. Patients with recurrent localized disease should be considered for resection with or without radiotherapy. A patient with metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered as initial therapy in patients with synchronous or metachronous resectable metastatic disease (i.e., neoadjuvant therapy) or when a response to chemotherapy may convert a patient from an unresectable to resectable state (i.e., conversion therapy). Other options for patients with resectable synchronous metastases are initial treatment with chemoRT or chemotherapy with or without a bevacizumab or cetuximab (KRAS wild type tumor only) followed by consolidating chemoRT. Resection should be followed by adjuvant therapy based on prior therapy received. The recommended post-treatment surveillance program for rectal cancer patients includes serial CEA determinations, as well as periodic chest, abdominal and pelvic CT scans, and periodic evaluations by colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at the start of therapy include pre-planned strategies for altering therapy for patients in both the presence and absence of disease progression, including plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy options for advanced or metastatic disease depend on whether or not the patient is appropriate for intensive therapy. The more intensive initial therapy options include FOLFOX, FOLFIRI, CapeOX, and FOLFOXIRI (category 2B). Addition of a biologic agent (e.g., bevacizumab or cetuximab) is either recommended, or listed as an option, in combination with some of these regimens, depending on available data. Chemotherapy options for patients with progressive disease are dependent on the choice of initial therapy. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.",
keywords = "Adjuvant chemotherapy, Adjuvant radiotherapy, Colorectal surgery, Fluorouracil, Irinotecan, NCCN clinical practice guidelines, Neoplasm recurrence, Neoplasm staging, Oxaliplatin, Rectal neoplasms",
author = "Engstrom, {Paul F.} and Arnoletti, {Juan Pablo} and Benson, {Al B.} and Chen, {Yi Jen} and Choti, {Michael A.} and Cooper, {Harry S.} and Anne Covey and Dilawari, {Raza A.} and Early, {Dayna S.} and Enzinger, {Peter C.} and Fakih, {Marwan G.} and James Fleshman and Charles Fuchs and Grem, {Jean L} and Krystyna Kiel and Knol, {James A.} and Leong, {Lucille A.} and Edward Lin and Mulcahy, {Mary F.} and Sujata Rao and Ryan, {David P.} and Leonard Saltz and David Shibata and Skibber, {John M.} and Constantinos Sofocleous and James Thomas and Venook, {Alan P.} and Christopher Willett",
year = "2009",
month = "9",
doi = "10.6004/jnccn.2009.0057",
language = "English (US)",
volume = "7",
pages = "838--881",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Rectal cancer

AU - Engstrom, Paul F.

AU - Arnoletti, Juan Pablo

AU - Benson, Al B.

AU - Chen, Yi Jen

AU - Choti, Michael A.

AU - Cooper, Harry S.

AU - Covey, Anne

AU - Dilawari, Raza A.

AU - Early, Dayna S.

AU - Enzinger, Peter C.

AU - Fakih, Marwan G.

AU - Fleshman, James

AU - Fuchs, Charles

AU - Grem, Jean L

AU - Kiel, Krystyna

AU - Knol, James A.

AU - Leong, Lucille A.

AU - Lin, Edward

AU - Mulcahy, Mary F.

AU - Rao, Sujata

AU - Ryan, David P.

AU - Saltz, Leonard

AU - Shibata, David

AU - Skibber, John M.

AU - Sofocleous, Constantinos

AU - Thomas, James

AU - Venook, Alan P.

AU - Willett, Christopher

PY - 2009/9

Y1 - 2009/9

N2 - The NCCN Rectal Cancer Guidelines panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important with a goal of evaluating at least 12 nodes when possible. Patients with very early stage tumors lesions that are node-negative by endorectal ultrasound or endorectal or pelvic MRI and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for the majority of patients with suspected or proven T3/T4 disease and/or regional node involvement and adjuvant chemotherapy is recommended. Patients with recurrent localized disease should be considered for resection with or without radiotherapy. A patient with metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered as initial therapy in patients with synchronous or metachronous resectable metastatic disease (i.e., neoadjuvant therapy) or when a response to chemotherapy may convert a patient from an unresectable to resectable state (i.e., conversion therapy). Other options for patients with resectable synchronous metastases are initial treatment with chemoRT or chemotherapy with or without a bevacizumab or cetuximab (KRAS wild type tumor only) followed by consolidating chemoRT. Resection should be followed by adjuvant therapy based on prior therapy received. The recommended post-treatment surveillance program for rectal cancer patients includes serial CEA determinations, as well as periodic chest, abdominal and pelvic CT scans, and periodic evaluations by colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at the start of therapy include pre-planned strategies for altering therapy for patients in both the presence and absence of disease progression, including plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy options for advanced or metastatic disease depend on whether or not the patient is appropriate for intensive therapy. The more intensive initial therapy options include FOLFOX, FOLFIRI, CapeOX, and FOLFOXIRI (category 2B). Addition of a biologic agent (e.g., bevacizumab or cetuximab) is either recommended, or listed as an option, in combination with some of these regimens, depending on available data. Chemotherapy options for patients with progressive disease are dependent on the choice of initial therapy. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

AB - The NCCN Rectal Cancer Guidelines panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important with a goal of evaluating at least 12 nodes when possible. Patients with very early stage tumors lesions that are node-negative by endorectal ultrasound or endorectal or pelvic MRI and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for the majority of patients with suspected or proven T3/T4 disease and/or regional node involvement and adjuvant chemotherapy is recommended. Patients with recurrent localized disease should be considered for resection with or without radiotherapy. A patient with metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered as initial therapy in patients with synchronous or metachronous resectable metastatic disease (i.e., neoadjuvant therapy) or when a response to chemotherapy may convert a patient from an unresectable to resectable state (i.e., conversion therapy). Other options for patients with resectable synchronous metastases are initial treatment with chemoRT or chemotherapy with or without a bevacizumab or cetuximab (KRAS wild type tumor only) followed by consolidating chemoRT. Resection should be followed by adjuvant therapy based on prior therapy received. The recommended post-treatment surveillance program for rectal cancer patients includes serial CEA determinations, as well as periodic chest, abdominal and pelvic CT scans, and periodic evaluations by colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at the start of therapy include pre-planned strategies for altering therapy for patients in both the presence and absence of disease progression, including plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy options for advanced or metastatic disease depend on whether or not the patient is appropriate for intensive therapy. The more intensive initial therapy options include FOLFOX, FOLFIRI, CapeOX, and FOLFOXIRI (category 2B). Addition of a biologic agent (e.g., bevacizumab or cetuximab) is either recommended, or listed as an option, in combination with some of these regimens, depending on available data. Chemotherapy options for patients with progressive disease are dependent on the choice of initial therapy. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

KW - Adjuvant chemotherapy

KW - Adjuvant radiotherapy

KW - Colorectal surgery

KW - Fluorouracil

KW - Irinotecan

KW - NCCN clinical practice guidelines

KW - Neoplasm recurrence

KW - Neoplasm staging

KW - Oxaliplatin

KW - Rectal neoplasms

UR - http://www.scopus.com/inward/record.url?scp=70349865073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349865073&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0057

DO - 10.6004/jnccn.2009.0057

M3 - Review article

C2 - 19755047

AN - SCOPUS:70349865073

VL - 7

SP - 838

EP - 881

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 8

ER -